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ABSTRACT
 
Efficacy of Gold Silica nanoshells and Gold NanoABSTrods for  
Photothermal Therapy of Human Glioma Spheroids 
 
By 
 
Suyog J. Chhetri 
 
Dr. Steen Madsen, Examination Committee Chair 
Chair, Professor of Health Physics and Diagnostic Sciences 
University of Nevada, Las Vegas 
  
Gold-based nanoparticles including gold-silica nano-spheres and gold nano-rods 
have been investigated for a number of therapeutic and diagnostic applications. The 
ability of these nanoparticles to convert light into heat energy makes them particularly 
appealing for photothermal therapy in which cancer cells are destroyed via light-induced 
heat generation. The overall objective of the study is to compare the efficacy of gold-
silica nano-spheres and gold nano-rods in an in vitro system consisting of human brain 
tumor (glioma) spheroids. 
Delivery of the nanoparticles to the spheroids was accomplished using murine 
macrophages. Nanoparticles (spheres or rods) were incubated with macrophages for 24 
hours. Thereafter, nanoparticle-loaded macrophages were combined with human glioma 
cells and centrifuged in order to create a hybrid spheroid. Approximately 48 hours post 
centrifugation, the resultant 400 µm dia. spheroids were exposed to 808 nm laser light for 
10 min at irradiances of 2, 7, 14 and 28 W cm
-2
. Treatment efficacy was evaluated from 
spheroid growth kinetics over a 14-day period.  
Gold nanoshells were shown to have greater efficacy compared to gold nanorods. 
For example, hybrid spheroids consisting of a 5:1 ratio of glioma cells to nanosphere-
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loaded macrophages exhibited significant growth inhibition when subjected to irradiances 
of 7 W cm
-2
. In contrast, no growth inhibition was observed for the nanorod-macrophage 
hybrid spheroids, even at the highest irradiance investigated (28 W cm
-2
). Growth 
inhibition was observed at 28 W cm
-2
 when the nanorod concentration was increased, i.e., 
by forming hybrid spheroids with a 2:1 ratio of glioma cells to macrophages. 
Gold nano-spheres are better photo-thermal agents compared to gold nanorods. 
The work highlights the potential of gold nano-spheres in the treatment of brain tumors 
using laser-induced photothermal therapy as an adjuvant to conventional therapies.  
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Chapter 1: Introduction 
1.1 Glioblastoma Multiforme 
 
Glioblastoma multiforme (GBM) originate from glial cells which are support cells 
for neurons. GBM is the most common and malignant type of primary brain tumor in 
adults, and because of its aggressive and invasive nature, there are no effective therapies.  
With the exception of the brainstem gliomas, GBM has the worst prognosis of any central 
nervous system (CNS) malignancy (Hart et al. 2008, Martin et al. 2009). Cellular origins 
and histologic appearance are used as the basis for classifying primary brain tumors. For 
example, astrocytomas which originate from astrocytes, constitute the majority of CNS 
tumors (Chandana et al. 2008). Using histologic appearance as the bases for tumor 
classification, astrocytomas can be graded as pilocytic astrocytoma (grade I), astrocytoma 
(grade II), anaplastic astrocytoma (grade III), or glioblastoma multiforme (grade IV) 
(Gomez and Kruse, 2006; Hoelzinger et al. 2007; Hart et al. 2008; Maru et al. 2008; 
Yamanaka 2008) .  Grade I and II tumors are considered low grade while grades III and 
IV are highly proliferative and have the potential to disperse to distant sites which makes 
their eradication more difficult than lower grade tumors (Hoelzinger et al. 2007, 
Chandana et al. 2008). GBM is the most common type of glioma (Figure 1) and the most 
malignant form of astrocytoma (Gomez and Kruse 2006, Chandana et al. 2008, La Rooca 
and Mehdorn 2009).  
Characteristic features of GBM include large populations of poorly differentiated 
and pleomorphic cells, endothelial proliferation, tissue invasion, angiogenesis and 
necrosis. GBM is often resistant to apoptotic stimuli and the tumor cells are not 
recognized by the immune system. Symptoms are many and varied and are related to 
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location, size, and growth rate, but they most commonly include seizures, headaches, 
speech difficulties, and changes in mental status. 
GBM is relatively rare (3 cases per 100 000 in the United States) and is more 
common among Caucasians. In the absence of any form of therapy, median survival is 
less than three months. With standard therapeutic regimens consisting of surgery, 
radiation and chemotherapy, median survival ranges from 12 to 18 months (Madsen et al. 
2006).  
 
 
 
 
Figure 1: The incidence of CNS gliomas (La Rooca and Mehdorn 2009). 
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Patients have a high frequency of recurrence due to the highly invasive nature of 
the tumor: median survival after initial treatment is only 25 weeks, and patients have a 
relatively poor quality of life due to the detrimental effects of aggressive therapies 
(Hoelzinger et al 2007). About 90% of GBMs arise from glial cells and are termed 
primary GBMs. These are more common in older patients and have a typical clinical 
history of less than 6 months. Secondary GBMs transform over months or years from 
preexisting lower-grade gliomas and occur predominantly in younger patients (Chandana 
et al. 2008; Maru et al. 2008; Sathornsumetee and Rich 2008; Reardon and Wen 2006). 
1.2 Biology and Molecular Characteristics of GBM 
 
In GBM, there are indications of genetic alterations which include cell cycle 
regulatory pathways (p53 and p16), growth factor receptors, and signaling pathways 
(Figure 2). Although primary and secondary GBMs have many genetic abnormalities in 
common, secondary GBM is characterized by the inactivation of the TP53 gene which is 
important in inducing cell cycle arrest and initiating DNA repair in response to geno-
toxic stress and, as a result, the inactivation is associated with abnormal cell division. 
Mutations of the tumor-suppressor gene p53 have been reported in 30-60% of malignant 
gliomas, and are more common in secondary than primary GBMs (Selznick et al. 2008; 
Yamanaka 2008). Along with TP53 gene inactivation, secondary GBMs have an 
overexpression of the platelet derived growth factor (PDGF) and its receptors which has 
been implicated in tumor cell proliferation in both early and late stages of glioma 
development (Sathornsumetee and rich 2008; Yamanaka 2008; Reardon and Wen 2006). 
While primary GBM is characterized by overexpression (>60% of cases) of the epidermal 
growth factor receptor (EGFR) gene, is involved in the control of cell proliferation.  
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The up-regulation of EGFR has been positively correlated with GBM malignancy, and its 
defect can also increase activity of an important signaling pathway such as the 
phosphatidyliositide-3-kinase (PI3K)/AKT pathway which controls cellular processes 
that contribute to normal homeostasis and malignancy (Figure 2). Primary GBM also 
exhibits amplification and overexpression of murine double minute 2 (MDM2), a protein 
which forms a complex with tumor protein 53 (TP53), as a result abolishing the control 
of cell growth (Selznick et al. 2008).  
 
 
 
 
 
Figure 2: Genetic abnormalities of primary and secondary GBM (Sathornsumetee and Rich 2008) 
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1.3 Diagnosis and Prognosis 
 
The poor prognosis of GBM patients is due primarily to the infiltrative nature of 
the disease and despite advances in its management, several factors prevent the complete 
eradication of GBM.  Currently, biopsy is the gold standard for GBM diagnosis since it 
provides histological information that can be used to determine the potential 
aggressiveness and hence, mean survival time (Baek et al. 2011; Chandana et al. 2008). 
With recent advances in imaging, it is now possible to perform deep brain biopsies with 
accurate tumor localization. Although CT and MRI have been used for diagnosis and 
treatment planning, these modalities suffer from an inability to accurately delineate tumor 
margins due to edema build-up associated with the tumor vasculature. The outcome of 
patients with GBM is influenced by their age, neurological status, tumor location, 
histological and molecular features and extent of surgical resection. The age of the patient 
is a significant prognostic factor. Trials have shown that half the patients under the age of 
40 survive for 18 months compared to 10% of patients older than 60 (Baek et al. 2011).  
The location of the tumor is also an important prognostic indicator: tumors 
located in the deep gray matter are associated with a better prognosis compared to that of 
lobar tumors, and patients with frontal lobe tumors have a better prognosis than those 
with tumors located in the temporal or parietal lobes. A significant limiting factor of 
GBMs to therapy is their physical isolation by the blood-brain barrier (BBB) which is 
formed by tightly connected brain capillary endothelial cells. Although this barrier serves 
a protective function by preventing entry of pathogens into the brain, it also acts as a 
barrier for anti-cancer agents including chemotherapeutics (Makkouk 2011). 
Furthermore, tumor resection is greatly hindered by the poor visual contrast between 
6 
 
cancerous and normal brain tissue and an aggressive gross resection often impairs the 
patient’s quality of life while a limited resection may leave residual glioma cells in the 
margins. Genetic variability is another limiting factor that has created resistance to both 
chemotherapy and radiation therapy (Gomez and Kruse 2006, Sathornsumetee and Rich 
2008; Maier-Hauff et al.  2007; Parvez 2008; Debinski 2008). 
1.3.1 Surgery 
 
Following diagnosis, the management of GBM is based on symptomatic relief and 
increasing survival with multimodality treatments. Currently, the primary treatment for 
GBM is surgical resection to remove the tumor mass causing the symptoms. The primary 
goal is to achieve maximal resection while preserving neurological function and, despite 
being surgically incurable, resection improves functional status and prolongs survival 
(Parvez 2008). The extent of resection is based on several factors, including location, 
histopathology, and presence of comorbid conditions. To minimize damage to crucial 
structures, CT and MRI are used to guide resection in real time to assess tumor volume 
and delineate critical areas of normal brain (Koo et al. 2006; Reardon and Wen 2006; 
Chandana et al. 2008; Hart et al. 2008). 
1.3.2 Radiation therapy 
 
In almost all cases, resection alone is insufficient and other therapies, including 
radiation, are employed to destroy malignant cells in the brain adjacent to tumor (Koo et 
al. 2006; Parvez 2008). For example, randomized studies have shown increases in median 
survival up to nine months with 50-60 Gy of whole brain radiation following surgery 
(Reardon and Wen 2006). Radiation therapy can be delivered either externally or 
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internally. In addition to whole brain irradiation, highly conformal techniques, commonly 
referred to as stereotactic radiosurgery, are often used for the delivery of high doses to the 
lesion while sparing normal brain. Interstitial radiation therapy using I-125 seeds 
implanted into the margin following surgery has also been attempted. This low dose-rate 
approach may be more effective from a biological point of view compared to the high 
dose-rate external beam techniques (Chandana et al. 2008; Parvez 2008). Overall, the 
limitations of radiation include the presence of resistant cells, radiation-induced decline 
in cognitive function and the risk of secondary malignancies (Koo et al. 2006).  
1.3.3 Chemotherapy 
 
The inability of the vast majority of chemotherapeutic agents to penetrate the 
intact blood-brain barrier has limited their utility in the treatment of brain tumors. (Koo et 
al. 2006). Furthermore, the problem of multi-drug resistance, resulting in cells actively 
pumping out therapeutic compounds, has necessitated the use of chemotherapeutic 
cocktails consisting of a number of compounds (Koo et al. 2006; Hart et al 2008). For 
example, the standard combination of drugs consisting of Procarbazine, Lomustine, and 
Vincristine, has been shown in a meta-analysis to be associated with a two month 
improvement in median survival (Parvez 2008).  
Recently, temozolomide (TMZ) has shown significant clinical benefit. GBM 
patients treated with TMZ and radiation showed median survival of 14.6 months and 
TMZ has also been shown to be effective as a primary therapy for GBM without a 
significant risk of early adverse events. The efficacy of this drug is likely associated with 
its ability to penetrate the intact blood-brain barrier (Hart et al. 2008; Koo et al. 2006). 
8 
 
1.3.4 Laser Interstitial Thermotherapy 
 
The ineffectiveness of current GBM therapies has provided the impetus for the 
development of new approaches including laser-based techniques such as laser interstitial 
thermotherapy (LITT) (Menovsky et al.1996). LITT is based on the principle that 
absorption of light is converted to heat which in turn causes tumor ablation through 
coagulation. A key to the use of laser irradiation is the ability to localize light delivery 
(and hence, heat distributions) to the tumor tissue while keeping temperatures in 
surrounding normal brain below the damage threshold (approximately 43
o
C). This has 
traditionally been accomplished via interstitial insertion of optical fibers and 
thermocouples for feedback control of temperatures in the tumor and normal brain. A 
more recent, and less invasive approach, makes use of magnetic resonance imaging to 
monitor real-time temperature distributions during laser heating. 
Pre-clinical studies have shown that LITT efficacy depends on a number of 
factors including laser wavelength. Since tissues (including the brain) absorb strongly at 
short wavelengths, laser light in the 400-600 nm range  is absorbed rapidly resulting in 
treatment times of the order of several minutes (Kangasniemi et al. 2004). Unfortunately, 
the rapid increase in energy absorption increases the risk of unintended tissue heating and 
tissue carbonization which can produce inhomogeneous temperature distributions and 
unwanted heating of normal tissue (Atsumi et al. 2001). The use of near-infrared 
absorbing nanoparticles has the potential to improve temperature distributions in tumor 
tissue and thereby increase the therapeutic efficacy of LITT (Hirsch et al. 2006).  
9 
 
1.4 Nanoparticles 
 
There has recently been an increased interest in the use of nanoparticles in both 
diagnostic and therapeutic medicine. This is due to a number of factors including the 
ability to control their shape, size, and synthesis, as well as the ability to manipulate their 
optical properties (Lin et al. 2005). Gold-based nanoparticles are particularly attractive 
due to their low toxicity and ease of biomolecule conjugation to their surface (Hirsch et 
al. 2006; Everts 2007). Nanoparticles such as gold nanorods and nanoshells have been the 
subject of intense study since their dimensions and/or composition can be tailored for 
optimum absorption of near-infrared light (Figure 3) which has significant penetration in 
biological tissues (Huang et al. 2006). 
 
 
 
Figure 3: The effect of increasing the core: shell ratio on the plasmon resonance absorption wavelength of gold nano-shells 
(Hirsch et al. 2006) 
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Furthermore, compared to photo-thermal dyes, the absorption cross section of 
nanoparticles can be up to five orders of magnitude higher (Loo 2004). Taken together, 
these properties can be used to create localized heating or drug release, thus providing the 
basis for therapeutic applications. 
Photon interactions with nanoparticles are dominated by scattering or absorption. 
For the purposes of therapeutic applications, nanoparticles with high absorption and low 
scattering cross sections are ideal (Aslan et al. 2005). Light interacts with nanoparticles 
via the plasmon resonance effect, i.e., the collective oscillation of free electrons at 
metallic surfaces which causes metallic nanoparticles to absorb and scatter 
electromagnetic radiation of wavelengths much larger than the particles. Excitation of 
surface electrons via photon absorption results in a heated electron gas that cools by 
exchanging its excitation energy with the nanoparticle lattice via electron-phonon 
interactions. The lattice itself cools within 100 ps by dissipating the energy to the 
surrounding medium via photon-photon interactions (Huang et al. 2006; Huang et  al. 
2008).Conversion of light energy to heat is optimized by using a laser at a wavelength 
that overlaps with the nanoparticle’s single plasmonic resonance (SPR) wavelength. This 
approach has been used in cancer therapeutics and is known as plasmonic photo-thermal 
therapy (PPTT).  
In the case of gold, the plasmon resonance effect is optimal at a wavelength of 
approximately 520 nm corresponding to green light. A fraction of the incident light is 
scattered, but the fraction of light absorbed will cause heating thus resulting in a localized 
increase in temperature, which can be exploited for photo-thermal therapeutic uses (Roco 
1999; Cile et al. 2009). Since the peak absorption of gold nanoparticles occurs at a short 
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wavelength, where tissue penetration is relatively low, their utility in therapeutic 
applications is rather limited. In contrast, gold nanoshells and gold nanorods have strong 
absorption in the near-infrared. In the case of nanoshells, the exact absorption peak 
depends on the ratio of gold shell to silica core thickness: as the shell thickness decreases, 
the peak absorption shifts to longer wavelengths (Cole et al. 2009). Two absorption bands 
are observed for gold nanorods; a strong band in the near infrared (NIR) region that is 
due to the oscillation of electrons along the longitudinal axis, and a weaker band in the 
visible region due to the transverse electronic oscillation (Huang et al. 2006; Huang et al. 
2008). In this case, the peak absorption wavelength depends on the aspect ratio (length-
to-width) of the nanorod. 
As with any cancer therapy, the goal of nanoparticle-based hyperthermia is the 
destruction of tumor tissue while avoiding excessive heating of normal tissues - a 
common problem with well-established hyperthermia techniques such as radiofrequency 
(RF) and magnetic thermal ablation (Huang et al. 2008; Liu 2008). Tissue heating can be 
minimized by use of laser radiation of wavelengths in the “tissue optical window” which 
lies in the visible and NIR regions. Biological tissues lack NIR-absorbing chromophores, 
which allows optimal transmission of NIR light (700-1000 nm) with minimal heating 
(Hirsch et al. 2003).  
Silica-gold nanoshells have strong and tunable absorption in the NIR region so 
that the combination of two benign moieties, nanoshells and NIR light, allows for 
selective heating of tumors loaded with gold nanoparticles. Most PPTT studies have 
employed diode lasers with wavelengths of 805-810 nm (Terentyuk et al. 2009). In order 
to achieve thermal ablation, tissues are heated to temperatures in excess of 50
o
 C, where 
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the tumors are selectively destroyed due to their poor blood supply and subsequent low 
heat tolerance (Huang et al. 2006).  
Optimal PPTT requires preferential localization and/or retention of nanoparticles 
in tumor tissues. Nanoparticle specificity is a natural consequence of the tumor 
vasculature which consists of rapidly formed defective vessels with large intercellular 
gaps (≤ 2 µm) allowing passage of large compounds from the circulation into tumors. 
This passive process is termed “enhanced permeability and retention (EPR)” (H6irsch et 
al. 2006; Zaman et al. 2007; Bernardi et al. 2008). Significant accumulation of 
nanoparticles in tumors via the EPR effect is complicated by their removal from the 
circulation by macrophages, in particular the Kupffer cells of the liver (Tortora et al. 
1995; Cuenca et al.2006; Hirsch et al. 2006; Hamoudeh et al. 2008; Terentyuk et al. 
2009). A simple strategy to avoid detection by the immune system is to coat the surfaces 
of the nanoparticles with a polymer such as polyethylene glycol (PEG) (Hirsch et al. 
2006; Everts 2007). Although nanoshell accumulation via the EPR effect has been 
observed in a wide variety of tumors, it may be insufficient for effective PPTT. This has 
provided the impetus for the development of “active” approaches including the use of 
delivery vectors such as macrophages. 
1.5 Macrophages 
 
 Macrophages are classified as white blood cells that originate from myeloid 
progenitor cells located in the bone marrow. Monocytes are the precursors that 
differentiate into macrophages once they migrate from the circulation into the tissue 
where they reside (Owen et al. 2004; Murdoch and Lewis 2005). Macrophages are the 
first to mediate host immune responses against foreign objects. Along with their role in 
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phagocytosis or ingestion of invading pathogens, macrophages also release several 
growth factors such as cytokines and interleukins (e.g. transforming growth factor-β 
(TGF-β) and platelet-derived growth factor), and they are involved in a number of other 
inflammatory responses as well as in the repair of damaged tissues (Metz et al. 2004; 
Hsiao  et al.  2008).  
1.5.1 Tumor-Associated Macrophages 
 
In addition to neoplastic cells and blood vessels, tumors are infiltrated by 
leukocytes, in particular macrophages which represent an important component. These 
macrophages are known as tumor-associated macrophages (TAMs) which are monocytes 
that are recruited into the tumor and comprise up to 50% of the tumor’s cellular mass 
(Murdoch and Lewis 2005; Knowles and Harris 2007). In the case of GBM, it has been 
observed that TAMs can constitute up to a third of the tumor mass. In addition, high 
concentrations of macrophages are commonly observed along the tumor margins 
(Jackson et al. 2007; VanHandel et al. 2009).  For a tumor to be able to utilize 
macrophages for their benefit, the macrophages must first be recruited, and to achieve 
this, tumors induce a chemo attractive gradient by secreting a number of factors, the most 
important of which are chemokines (Choi et al. 2007).  
Many solid tumors are characterized by large hypoxic and/or necrotic regions that 
occur when the growth rate exceeds the rate of angiogenesis. The necrotic core influences 
tumor aggressiveness, response to therapy, and the patient’s overall survival. The hypoxic 
cells surrounding the necrotic core adapt by reducing their proliferation rate which 
renders them less responsive to chemotherapies that kill more active and dividing tumor 
cells and, as a result, negatively impacts overall survival. Tumor cells in the hypoxic 
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regions are also less responsive to radiotherapy due to the absence of oxygen-formed free 
radicals that are important for radiation-induced DNA damage. Interestingly, TAMs have 
been observed in large numbers in hypoxic tumors where they might be attracted by cells 
undergoing necrosis.  
1.5.2 Use of Macrophages 
 
Macrophages have become a very attractive vector for the delivery of therapeutic 
agents due to their ability to migrate and accumulate within tumor tissue, specifically in 
hypoxic regions. Of particular relevance to this work was the recent study by Valable et 
al. (2009) who injected rats with iron oxide-loaded macrophages followed by magnetic 
resonance imaging which showed macrophage accumulation in and around brain tumors.  
An advantage of using such a cell-based delivery system is the increase in the 
nanoparticles’ systemic half-life since the macrophages protect against 
reticuloendothelial elimination. From a clinical perspective, the basic procedure for such 
a strategy involves isolation of macrophages from a given patient followed by  
macrophage loading of the agent of interest (e.g. nanoparticles) which are then injected 
into the patient (Owen et al. 2004; Murdoch and lewis 2005; Knowles and Harris 2007).  
1.6 Spheroids 
 
Three-dimensional spherical cell clusters (spheroids) consisting of a mixture of 
murine macrophages and human glioma cells were used in this work. Spheroids mimic 
tumor nodules and metastasis and they have been used to study the effects of therapies on 
fundamental biological mechanisms including regulation of proliferation, cell death, 
differentiation, metabolism, invasion, immune response and angiogenesis (Sutherland 
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1988). In contrast to monolayer cultures, the microenvironment of multicellular spheroids 
more closely mimics the in vivo situation and therefore, gene expression and the 
biological behavior of the cells are likely similar to that encountered in tumor cells in situ 
(Madsen et al. 2006).  
As with solid tumors, spheroids are characterized by significant oxygen gradients 
resulting in a similar type of cell heterogeneity as observed in vivo. For example, a 
necrotic core forms in spheroids at distances of 50-300 µm from their surface due to 
inadequate oxygenation. The exact location of the necrotic core depends on a number of 
factors including cell type, substrate consumption rates, growth media conditions and cell 
density (Sutherland 1988). In general, the vast majority of proliferating cells are found in 
the outer three to five cell layers of the spheroid (ca. 75 µm) and a layer of oxygen-
starved quiescent cells are found near the necrotic core. These cells can be recruited into 
the cycling population under the appropriate environmental conditions and, as such, they 
represent the population of cells resistant to oxygen-dependent therapies such as ionizing 
radiation and photodynamic therapy (Madsen et al. 2006).  
In addition to oxygenation status, tumor response to therapies is controlled by a 
number of parameters including intracellular contact and communication and 
susceptibility to apoptosis (Olive and Durnad 1994). Monolayer cultures are inadequate 
for investigating these parameters as they are unable to mimic oxygen gradients and the 
complex intracellular adhesion found in 3-D spheroids. Furthermore, the lack of an 
extracellular matrix in monolayer cell suspensions affects their response to most therapies 
(Madsen et al. 2006). Since survival and cell death (especially apoptosis) are sensitively 
dependent on both cell adhesion and the extracellular matrix (Santini et al. 2000), results 
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obtained in monolayers are likely not a true indicator of in vivo therapeutic efficacy, 
hence providing the rationale for 3-D multi-cell spheroids. 
1.7 Scope of Study 
 
The overall objective of the thesis is to compare the PPTT efficacy of gold silica 
nanoshells and gold nanorods. This was accomplished via two specific aims. In the first 
part, the uptake efficacy of the two types of nanoparticles was evaluated in murine 
macrophages. Based on this data, the concentration of nanoparticles will be evaluated in 
murine macrophages.  
The second aim is to investigate the optical to thermal conversion efficacy for the 
two types of nanoparticles. This was determined by NIR laser irradiation (808 nm) of 
hybrid spheroids consisting of human glioma cells and nanoparticle-loaded murine 
macrophages. Overall, PPTT efficacy will be evaluated by monitoring spheroid growth 
kinetics following laser irradiation. Due to their smaller size, it is hypothesized that 
nanorod uptake have greater than nanoshell uptake. Additionally, it is hypothesized that 
the larger nano-shells have a higher optical to thermal conversion efficiency compared to 
the nano-rods. The overall concept of laser-mediated PPTT using macrophages as vectors 
for nanoparticles in multicellular spheroids is illustrated in Figure 4.  
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Figure 4: Model of macrophage endocytosis of nanoparticles and incorporation into tumor spheroids followed 
by laser-mediated thermal ablation (Makkouk and Madsen  2013). 
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Chapter 2: Materials and Methods 
 
2.1 Cell lines 
 
Two cells lines were used: murine macrophages (P388D1; ATCC# CCL-46) and 
human grade IV GBM cells (ACBT; G. Granger, University of California, Irvine). Both 
cell lines were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM; Life 
Technologies Corp., Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS), 25 
mM HEPES buffer (pH≈7.4), 100 U/mL of penicillin and 100 ug/mL of streptomycin. 
ACBT is an adherent cell line and is maintained as a monolayer, while the P388D1 
macrophage line is grown in suspension.  ACBT cells were grown to confluency in an 
incubator (37
o
 C, 5.0% CO2 and 95% humidity). The confluent flasks were emptied of 
media and washed with Gibco phosphate buffered saline (PBS) (Life Technologies Corp., 
Carlsbad, CA). Cells were detached using Gibco 0.25% Trypsin-EDTA (Life 
Technologies Corp., Carlsbad, CA) for 5 min. Following detachment a 1:5 dilution of 
ACBT cells with DMEM, cells were seeded in new T-25 flasks in order to maintain the 
cell line. In the case of P388D1, the cells were passed at a ratio of 1:100 of P388D1 to 
DMEM. 
2.2 Nanoparticles 
Two different types of nanoparticles were used in the study; gold nano-shells 
(AuroShell™) and gold nano-rods. Both were purchased from Nanospectra Biosciences 
Inc. (Houston, TX, USA). In both cases, nanoparticles were coated with polyethylene 
glycol (PEG) in order to prevent aggregation. Gold nanoshells were supplied as a 
suspension in deionized water (2.82 x 10
11
 particles/ml), and consisted of a 120-nm 
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diameter silica core encased in a gold shell of 15 nm thickness giving a total particle 
diameter of 150 nm. The peak absorption was found at a wavelength of 819 nm (optical 
density = 105). For the nanorods (length = 45nm; width = 15nm) the stock concentration 
was 2.0 x 10
11
 particles/mL with a peak absorbance at a wavelength of 765 nm (optical 
density = 1.09). The absorption spectra for both types of nanoparticles are shown in 
Figure 5. 
 
 
 Figure 5: Vis-NIR absorption spectra of (a) pegylated gold nano-shells (top) and (b) pegylated gold nano-rods 
(bottom).   
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2.3 Uptake of Nanoparticles 
 
Nanoparticle uptake by macrophages was studied using UV-Vis-NIR 
spectrometry. Macrophages (5.0 x 10
6
) were incubated with either PEGylated nano-shells 
(4.3 x 10
9
 per ml) for 24 h or an equivalent concentration of PEGylated nano-rods for 
varying times ranging from 2 to 36 h. In both cases, incubation was performed under 
standard conditions (37*C in 5% CO2 and 95% humidity). Past studies have shown that a 
concentration of  4.3 x 10
9
 nanoshells/mL and 5 million macrophages was optimal in 
terms of minimizing toxicity and maximizing uptake (Makkouk 2011). An equivalent 
nanorod concentration was chosen for comparative purposes.  
 Following incubation, macrophages were transferred to 15-ml centrifuge tubes, 
and centrifuged at 600 rpm for 7 min, then washed twice with PBS to remove un-
endocytosed particles, while centrifuging and discarding the supernatant in between 
washes. The final cell pellet was suspended in 3 ml DMEM, and the absorbance of the 
resultant cellular suspension measured with a Varian UV-Vis-NIR spectrophotometer 
(Cary 6000i, Varian, USA). 
Absorbance was measured over a spectral range of 600-1100 nm, which covers 
the broad absorption peak of both nanoshells (819 nm) and nanorods (765 nm). To 
calculate the percentage uptake of nanoparticles, reference solutions containing 
nanoparticles in absence of macrophages were used, and were prepared in the same 
solution (media) as that used for macrophage incubation, and at the same dilution ratio. 
Background correction is necessary to obtain absorbance values corresponding to 
nanoparticles only i.e. without medium interference. Consequently, solutions prepared by 
substituting the nanoparticle volume added with DI water were measured, and their 
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absorbance values subtracted from the nanoparticle solution absorbance values to give 
the pure absorbance of the nanoparticle. 
 The absorbance of ingested particles only i.e. without macrophage interference is 
needed to calculate percentage uptake. Consequently, macrophages incubated under 
similar conditions (same number, total volume, incubation time) in absence of 
nanoparticles were similarly washed and suspended in 3 ml DMEM. The resulting 
solution was measured, and its absorbance values subtracted from those of the 
macrophage groups to give the pure absorbance of the ingested nanoparticles. The 
percentage uptake of nanoparticles was calculated by: 
 
Where AM+ N is the absorbance of endocytosed nano-shells at λ= 819 nm (or nanorods at 
765 nm), and AN is the absorbance of the reference nanoshell (or nanorod) solution at the 
same wavelength. 
2.4 Hybrid Spheroid Formation 
 
Hybrid spheroids were formed using human ACBT cells and P388D1 murine 
macrophages. Nanoparticles (4.3 x 10
9
 per ml) were incubated with macrophages (5.0 x 
10
6 
per ml) under standard conditions 24 h prior to the formation of hybrid spheroids. 
After 24 h of incubation, macrophages were washed twice with PBS in order to remove 
non ingested nanoparticles. Prior to the formation of hybrids, macrophages were treated 
with mitomycin C to prevent macrophage division. Hybrid spheroids consisting of ACBT 
cells and empty macrophages served as controls. 
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 On the day of spheroid formation, ACBT cells (70% confluence) were harvested 
from the growth flasks and transferred to a centrifuge flask. A solution of 5000 ACBT 
cells/ml (10 ml total) and solutions of loaded (or unloaded) macrophages (both at 1000 
cells/ml were prepared. A 5:1 ACBT:macrophage solution was created by adding 5 ml 
ACBT cells to 5 ml of loaded macrophages. Finally, 200 µl of the mixture was pipetted 
into a 96-well plate for a final solution of 5000 ACBT cells and 1 000 macrophages per 
well. In one study, the effects of increasing the nanorod-loaded macrophage 
concentration were investigated. This was accomplished by decreasing the number of 
ACBT cells and increasing the macrophage number while keeping the total number of 
cells constant. In this case, 4000 ACBT cells were mixed with 2000 loaded macrophages. 
In all cases, the well plates were centrifuged at 1000 rpm for 10 min and thereafter hybrid 
spheroids were incubated under standard conditions for 48 hours. Following incubation, 
spheroid diameters typically ranged between 400 and 450 µm. At this point, the spheroids 
were prepared for laser irradiation. 
2.5 PPTT Treatment 
 
Prior to laser irradiation, spheroids were transferred to a clean 96-well plate (one 
spheroid per well). Every second well was left empty in order to minimize light scatter to 
non-irradiated spheroids. Prior to spheroid transfer, each well was filled with 200 µl 
DMEM. Irradiation was performed using a high power 808 nm diode laser (HPD-7404; 
Intense, North Brunswick, NJ). The output of the diode laser was coupled into a 600-µm  
dia. core optical fiber containing a collimating lens at its output end (FD1; Medlight, 
Ecublens, Switzerland). An additional lens assembly was attached to the fiber in order to 
focus the beam to the 3 mm diameter required for the experiments. Due to limitations of 
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the laser output (approx. 2 W), the high irradiances (up to 28 W cm
-2
) required for the 
experiments could only be achieved by focusing the beam. This posed a significant time 
constraint since only one spheroid could be irradiated at any given time. The output end 
of the optical fiber was placed in contact with the bottom of the well and each spheroid 
was irradiated for 10 min. at irradiances of 2, 7, 14 or 28 W cm
-2
,  The laser power was 
monitored every 20-30 min. and adjusted accordingly. Treatment efficacy was monitored 
from spheroid growth kinetics. This was accomplished by measuring spheroid diameters 
using an ordinary light microscope with a calibrated eyepiece. Measurements were made 
every 2-3 days over a 15day period. The DMEM medium was changed twice weekly 
during the observation period.   
 
 
 
 
 
 
 
 
 
Figure 6: Components of the laser system (Van Gemert MJC, 1995). 
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Chapter 3: Results 
3.1 Uptake of nanoparticles by murine macrophages 
 
 As illustrated in Figure 7, the uptake of nanorods by murine macrophages is 
greater than nanoshell uptake. Following 24 hours incubation, spectrophotometric 
analysis revealed uptakes of 3.9 ± 0.9 and 7.9 ± 0.7% for nanoshells and nanorods, 
respectively. Based on the initial nanoparticle concentrations, these uptakes correspond to 
337 nanoshells and 680 nanorods per macrophage, respectively. A p value of 0.04 was 
determined from a t-test between the mean nanoparticle values per macrophage. This 
suggests, the difference in uptake was statistically significant at the 95% confidence 
interval.   
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Figure 7: Comparison of gold nanoshell and gold nanorod uptake by murine macrophages. Equal concentrations of gold nanoshells and 
nanorods were incubated with macrophages for 24 h and uptake was evaluated from spectrophotometric analysis. The uptake difference 
was statistically significant (p < 0.05). 
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A study was initiated to determine whether nanorod uptake could be improved  
by increasing incubation times. The results are illustrated in Figure 8 and they show a 
rapid increase in uptake over the first 6 hrs, followed by a gradual increase to the 18 h 
time point. A rapid drop in uptake was observed for incubation times exceeding 24 h. 
Overall, the results provide justification for the 24 h incubation time as this is near 
optimal. 
3.2 Photothermal therapy of nanoparticle-loaded hybrid spheroids 
 In order to rule out the possibility of laser-induced thermal effects, control 
spheroids consisting of ACBT cells and empty macrophages were irradiated. The results 
(Figure 9) show minimal growth inhibition at all irradiances compared to the non-
irradiated controls. Spheroids in all five control groups grew to a diameter of 
approximately 1 mm at the end of the 14-day observation period. Overall, the results 
show that laser-induced thermal effects were insignificant over the range of irradiances 
investigated.   
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Figure 8: Uptake kinetics of nanorods by murine macrophages. Absorbance at 765 nm was used as a marker for nanorod uptake. Each 
data point corresponds to the mean of three trials and error bars denote standard deviations.  
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Figure 9: Growth kinetics of hybrid spheroids consisting of 5000 ACBT cells and 1000 empty murine macrophages were monitored. 
Following exposure to varying irradiances. Each data point represents the mean of three experiments and the error bars denote 
standard deviations.  Growth kinetics was monitored over 2 weeks. 
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Survival of nanoshell- and nanorod-loaded hybrid spheroids exposed to a range of 
laser irradiances are illustrated in Figure 10. No cytotoxicity was observed at the lowest 
irradiance investigated (2 W cm
-2
). In the case of the nanoshell-loaded spheroids, 
significant decreases in spheroid survival were observed at irradiances of 7 W cm
-2
 and 
higher. Spheroid survival was approximately 63, 56 and 40% at irradiances of 7, 14 and 
28 W cm
-2
, respectively. In the case of the nanorod-loaded spheroids, no significant 
diminution in survival (compared to empty hybrid controls) was noted at any of the 
irradiances investigated including the highest irradiance corresponding to 28 W cm
-2
. 
 
 
 
 
 
 
Figure 10: Survival of hybrid nanoshell (Tc+Ma/NS+PPTT) and nanorod (Tc+Ma/NR+PPTT) spheroids as a function of 
808 nm laser irradiance. Tc+Ma+PPTT denote hybrid control spheroids consisting of empty macrophages. Each data point 
corresponds to the mean of three trials and error bars denote standard deviations. 
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The growth kinetics of surviving nanoshell-loaded hybrid spheroids are shown in  
Figure 11. Compared to non-irradiated controls, significant growth delays were observed 
in hybrid spheroids subjected to irradiances ≥ 7 W cm-2. 
The growth kinetics of nanorod-loaded hybrid spheroids subjected to a range of 
near infrared laser irradiances are illustrated in Figure 12. The data show that, over the 
range of laser irradiances investigated, no statistically significant growth delays were 
observed compared to non-irradiated controls. Spheroids in all treatment and control 
groups reached a diameter of approximately 1 mm at the end of the 2 week observation 
period.  
 
Figure 11: Growth kinetics of nanoshell-loaded spheroids. Each data point corresponds to the mean of three experiments and error 
bars denote standard deviations. 
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An attempt was made to determine whether a thermal effect could be induced by 
increasing the number of nanorod-loaded macrophages in each spheroid. To that end, 
hybrid spheroids consisting of 4000 ACBT cells and 2000 nanorod-loaded macrophages 
were exposed to an irradiance of 28 W cm
-2
. The data presented in Figure 13 show a 
doubling of the number of nanorod-loaded macrophages results in a significant decrease 
in survival. For example, laser irradiation of hybrid spheroids consisting of 1000 
nanorod-loaded macrophages resulted in 87% survival which was not statistically 
different from the survival of the empty hybrid control spheroids (90%). In contrast, laser 
exposure of hybrid spheroids consisting of 2000 nanorod-loaded macrophages resulted in 
62% survival. Although a significant thermal effect was observed by doubling the 
number of nanorod-loaded macrophages, it was not as pronounced as the effect observed 
Figure 12: Growth kinetics of nanorod-loaded spheroids. Each data point corresponds to the mean of three experiments and error bars 
denote standard deviations. 
31 
 
for the spheroids containing 1000 nanoshell-loaded macrophages where exposure to 28 
W cm
-2
 resulted in a survival of 40%. 
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Figure 13: Hybrid spheroid survival as a function of nanorod-loaded macrophage concentration. All spheroids were subjected to 808 
nm laser irradiation at an irradiance of 28 W cm-2 and survival was recorded on day 14 post-irradiation. Each data point corresponds 
to the mean of three trials and error bars denote standard deviations. 
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Chapter 4: Discussion 
A number of in vitro and in vivo studies have been performed to evaluate the 
potential of gold-based nanoparticles for PPTT of brain tumors. Most studies have 
focused on gold-silica nanoshells as their properties are well characterized in comparison 
to other formulations (Makkouk and Madsen 2013). The first reported use of nanoshells 
for PPTT of brain tumors occurred in 2008 when Bernardi et al. (2008) used two different 
antibody conjugated nanoshells to target overexpressed receptors in high-grade human 
glioma and human medulloblastoma cell lines. Selective destruction of tumor cells 
overexpressing the selected biomarkers was observed following near infrared laser 
exposures of 9.6 kJ cm
-2
.  
A different targeting approach was investigated by Baek et al. (2011) who used 
macrophages as delivery vectors for gold-silica nanoshells. The in vitro model used by 
this group (hybrid spheroids consisting of human ACBT glioma cells and murine 
macrophages) was identical to that used in this work and the laser irradiation parameters 
provided the rationale for those used in the present study. Significant effects on spheroid 
growth were observed at near infrared laser irradiances as low as 7 W cm
-2
 (radiant 
exposure of 4.2 kJ/cm
2
). Overall, these findings are in excellent agreement with the 
results obtained in the present study showing significant spheroid growth inhibition at 
irradiances ≥ 7 W cm-2 (Figure 11).  
Cabada et al (2012) investigated the efficacy of gold nanorod-mediated PPTT in a 
high-grade human glioma cell line. They observed significant cell death following near 
infrared laser exposures of 1.4 kJ. Cell death was attributed to plasma membrane damage. 
A direct comparison with the results obtained in the present work is not possible due to 
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differences in the in vitro models (monolayer vs. spheroid) and the lack of information 
concerning intracellular nanorod concentrations in the monolayer model. Based on the 
results presented in Figure 13, much higher laser exposures were required to produce 
noticeable spheroid death (16.8 kJ/cm
2
 vs. 1.4 kJ/ cm
2
 for the monolayers). 
Of the two reported in vivo gold nano-shell PPTT brain tumor studies, one used a 
murine model (Day et al. 2011) while the other was accomplished in canines (Schwartz et 
al. 2009). In the latter study, tumors were established by injecting canine transmissible 
venereal tumor cells into canine brains. Passive accumulation of gold silica nano-shells 
was observed in tumors 24 h post i.v. administration. Thereafter, intracranial near 
infrared laser irradiation (0.63 kJ) resulted in near complete tumor ablation, with minimal 
damage to adjacent normal tissue. This study, in particular, provides the rationale for 
clinical trials.  
Although two in vivo gold nanorod PPTT studies have been reported (Dickerson 
et al. 2008; Von Maltzahn et al. 2009) neither involved brain tumor models. 
Nevertheless, both studies demonstrated significant tumor regression in murine models 
following near infrared laser irradiation of gold nanorod-loaded tumors.  
The delivery of nanoparticles to brain tumors is complicated by the presence of 
the BBB which protects the brain from circulating pathogens. Unfortunately, it also 
prevents entry into the brain of the vast majority of anti-cancer agents including the large 
nanoparticles investigated in this work. Although these nanoparticles are capable of 
entering brain tumors via passive diffusion through the leaky tumor vasculature (the EPR 
effect), the resultant intra-tumor distribution is often quite heterogeneous therefore 
providing the rationale for alternative delivery approaches such as those using exogenous 
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macrophages (Valable et al. 2007). Although such a technique might prove useful for 
destroying the tumor mass, its ability to eliminate nests of infiltrating glioma cells that 
have migrated into normal brain remains uncertain since these cells are protected by the 
patent BBB. A recent study by Madsen et al. (2013) demonstrated that exogenously 
administered nanoparticle-loaded macrophages were unable to traverse the BBB in 
normal rat brains suggesting elimination of infiltrating glioma cells requires targeted 
opening of the BBB prior to macrophage administration. This could be accomplished 
using a variety of targeted approaches including ultrasound, photodynamic therapy or 
photochemical internalization (Madsen and Hirschberg, In Review).  
Macrophages are efficient scavengers of pathogens and therefore it was hardly 
surprising that both types of gold nanoparticles were phagocytized by murine 
macrophages. As illustrated in Figure 7, approximately twice as many nanorods were 
ingested compared to nanoshells. The explanation for this observation is uncertain since 
the biophysical mechanisms of phagocytosis have not been well studied. The few studies 
that have been published have focused primarily on polymer micro-particles since these 
are similar in size to biologic pathogens (Champion et al. 2008). It is well established that 
size, shape and surface chemistry influence phagocytosis (Beningo and Wang 2002; 
Champion and Mitragotri 2006; Ahsan et al. 2002).  
For example, smaller particles are more readily phagocytized than larger ones as 
are particles with shapes similar to pathogens such as bacteria. Both of these observations 
would explain the results presented in Figure 7. The effects of surface chemistry on 
phagocytosis have been studied extensively. It is well known that the addition of a 
polyethylene glycol coating impairs phagocytosis by delaying opsonization, or adsorption 
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of proteins which enhance phagocytosis (Owens and Peppas 2006). It is precisely for this 
reason that PEGylated nanoparticles are used for in vivo applications – reduced 
macrophage uptake increases bio-distribution times and nanoparticle concentrations in 
target tissues. Both types of gold nanoparticles used in the studies described herein were 
PEGylated to prevent aggregation. Additional stabilization of nanorods was 
accomplished by the addition of small amounts of Cetyl trimethylammonium bromide 
(CTAB) thus altering the surface chemistry in comparison to the nanoshells.  
The addition of CTAB might explain the data in Figure 8 which show a 
significant decrease in absorbance for incubation times exceeding 24 hours. High 
concentrations (≥ 3.6 µg ml-1) of CTAB coated gold nanorods have been shown to be 
cytotoxic to human glioma cells (Fernandez Cabada et al. 2012). Although the 
concentration of CTAB nanorods used in the present studies (0.34 µg ml
-1
) was 
approximately 10 times lower, it’s possible that this was close to the cytotoxic limit since 
nanoparticle uptake by macrophages is expected to be much more efficient compared to 
uptake by glioma cells. It’s likely that, for incubation times exceeding 24 hours, the 
number of internalized CTAB nanorods exceeded the cytotoxicity threshold for murine 
macrophages. The effects of CTAB on macrophage viability could be investigated by 
removing the coating with hydrochloric acid (HCl).     
Silica core gold nanoshells and gold nanorods are the two most commonly used 
nanoparticles in PPTT (Young et al. 2012). The resonant coupling of incident light to the 
collective oscillation mode of the conduction electrons of noble metal nanoparticles 
(termed surface Plasmon resonance effect) produces enhancement in the optical 
absorption. It may also cause scattering when the particle is larger than a few tens of 
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nanometers. The optical response of metallic nanoparticles can be calculated from 
Maxwell’s equations, however, due to their computational complexity, approximations 
are typically used including Mie theory for spheres and the discrete dipole approximation 
for non-spherical geometries such as rods (Young et al. 2012). These models can be used 
to design scatter dominated or highly absorbing particles for diagnostic or therapeutic 
applications, respectively. 
Based on theoretical calculations, nano-spheres are predominantly scattering 
particles while extinction by nano-rods is primarily due to absorption. For example, 
calculations show that the nanoshells and nanorods used in the present work absorb 
approximately 12 and 93% of the incident light, respectively (Cole et al. 2009). However, 
nano-shells have a much larger cross-sectional area (and therefore a larger photothermal 
transduction cross-section) compared to the nanorods. Based on calculations by Jain et al. 
(2006), the absorption efficiency of the nanoshells used in this work is approximately ten 
times greater than that of the nanorods. Since the absorption efficiency is equivalent to 
the photothermal transduction efficiency (ignoring aggregation effects), this implies, the 
ratio of gold nanorods to nanoshells required for equivalent photothermal effect is 10:1.  
The PPTT results presented in Figures 10-13 are in good qualitative agreement 
with theoretical predictions. For example, the data show that, on a per nanoparticle basis, 
gold nanoshells have a higher photothermal transduction efficiency as determined from 
spheroid survival and growth inhibition. The nano-shell data presented in Fig. 10 is in 
good agreement with Baek et al (2011) who also found diminished spheroid survival at 
irradiances ≥ 7 W cm-2. In contrast, photothermal effects were minimal, or non-existent, 
for the nanorod-loaded spheroids over the irradiances investigated (Figures 10 and 12). 
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This is hardly surprising based on the nanorod-to-nanoshell ratio (2:1) in the hybrid 
spheroids as determined from the uptake studies shown in Figure 7.  
The effects of increased nanorod concentration were investigated by doubling the 
number of nanorod-loaded macrophages from 1000 (5:1 ACBT: macrophages) to 2000 
(2:1 ACBT: macrophages). As shown in Figure 13, increasing the nanorod-to-nanoshell 
ratio to 4:1 from 2:1, resulted in a decrease in spheroid survival by approximately 20%. 
As expected, even at this higher nanorod concentration, PPTT was less efficient 
compared to nanoshell PPTT as determined from spheroid survival (40% vs. 61%). As 
discussed previously, based on theoretical calculations, a nanorod-to-nanoshell ratio of 
approximately 10:1 is required for equivalent photothermal effects. Attempts to increase 
nanorod uptake by increasing incubation times were unsuccessful (Figure 8). Increasing 
the number of macrophages (and hence nanorods) was not attempted since this would 
likely result in unstable spheroid formation – macrophages are not known to form 
spheroids and therefore there is a practical limit to the number that can be used in hybrid 
spheroid formation.  
The results obtained in this work reinforce the findings of other studies showing 
that PPTT is not a very efficient treatment modality. As illustrated in Figure 10, a 
noticeable diminution in survival is only observed at radiant exposures ≥ 4.2 kJ cm-2 
corresponding to an irradiance of 7 W cm
-2
 and an irradiation time of 10 min. In 
comparison, significant photodynamic therapy effects in identical ACBT spheroids are 
observed at radiant exposures of only 2.5 J cm
-2
. In this context, it is difficult to envision 
the use of PPTT for the treatment of large tumor masses such as GBM where surgical 
resection is likely to remain the primary treatment. PPTT may be useful as an adjuvant 
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therapy for eliminating malignant cells in the resection margin and beyond following 
surgical resection. PPTT may also be useful for smaller, well-circumscribed lesions (e.g. 
brain metastases) since it can be delivered locally via interstitially implanted optical 
fibers thereby minimizing damage to surrounding normal brain. This is likely to result in 
a better quality of life compared to that achievable with standard therapies such as 
ionizing radiation. 
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Chapter 5: Conclusion 
  The purpose of this work was to compare the efficacy of gold nanoshells and 
nanorods in PPTT using a GBM spheroid model. Nano-rods are much smaller compared 
to nano-shells and this is likely the reason for their increased uptake by murine 
macrophages, e.g., the results presented herein show that nanorod uptake was 
approximately twice that of nano-shells for equivalent incubation times and particle 
concentrations. It was not possible to increase nanorod loading by using longer 
incubation times and, in fact, the standard 24 hours incubation period was near optimal. 
The sharp decline in nanorod uptake for incubation times exceeding 24 hours was 
attributed to CTAB-induced macrophage toxicity. Although relatively high laser 
irradiances were used in this work (7 – 28 W cm-2), they did not produce noticeable 
thermal effects in hybrid spheroids devoid of nanoparticles. A significant decrease in 
nanoshell-loaded spheroid survival was noted at irradiances of 7 W cm
-2
. In this case, the 
total energy delivered (radiant exposure) over the 10 min. irradiation period was 4.2 kJ 
cm
-2
. Spheroid viability decreased with increasing irradiance, ranging from 63% at 7 W 
cm
-2
 to 40% at 28 W cm
-2
. Significant growth inhibition was also observed for surviving 
nanoshell spheroids at irradiances ≥ 7 W cm-2, with the greatest inhibition noted for the 
highest irradiance.  
Laser exposure of nanorod-loaded spheroids did not produce statistically 
significant differences in either survival or growth kinetics compared to controls. A 
decrease in spheroid survival was only observed following a doubling of the number of 
nanorod-loaded macrophages. In this case, the total number of nano-rods exceeded that of 
nano-shells by a factor of four. Even at this higher nanorod concentration, PPTT was less 
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efficient (61% viability) compared to that obtained for the lower concentration nanoshell 
spheroids (40%).   
Overall, the results show that, on a per nanoparticle bases, gold-silica nano-
spheres have a greater photothermal efficiency compared to gold nano-rods. Theoretical 
calculations suggest the ratio of nano-rods to nano-shells required for equivalent PPTT 
effect is somewhat higher (approximately 10:1) than the 4:1 ratio used herein and this 
was likely the reason PPTT equivalency was not observed in these studies.   
A potential avenue for future research involves strategies for increasing nanorod 
uptake by murine macrophages. This could be accomplished simply by chemical removal 
of CTAB. If this approach fails to yield increased nanorod uptake, an alternative strategy 
to increase the nanorod-to-nanoshell ratio might be accomplished by deliberately 
decreasing nanoshell uptake, e.g., by decreasing incubation times. In either case, the goal 
would be to increase the nanorod-to-nanoshell ratio to 10:1, i.e., the ratio where 
theoretical calculations predict an equivalent effect for the two types of nanoparticles.  
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